AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors

In FY 2025, AbbVie Inc (NYSE:ABBV) reported revenue of nearly $61.2 billion, growing 8.7% from the previous year, with net income around $4.3 billion. Eli Lilly and Co (NYSE:LLY) achieved revenue of approximately $65.2 billion, a significant increase of 45% year-over-year, and net income around $20.6 billion. AbbVie's revenue is heavily reliant on Skyrizi and Rinvoq, while Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly contribute to its growth. Investors should note the differing risk profiles, with AbbVie facing patent expiration pressures and price reductions affecting certain products, which may influence investment choices.